ClearPoint Neuro, Inc.

AI-generated fair value estimate for this company.

Method: 10-year revenue-growth-driven DCF: $42.3M TTM revenue growing 20%/yr yrs 1-2 (2026 guidance of $48-52M; 'high-teens to 20%' 2027 guidance), then 18% yr3, 15% yr4, 12% yr5, 10% yr6, 8% yr7, 7% yr8, 6% yr9, 5% yr10; unlevered EBIT margin improving from -55% yr1 (vs -69% TTM actual) to -25% yr2, -5% yr3, then turning positive at 8% yr4, 15% yr5, 18% yr6, 20% yr7, 21% yr8, 22% yrs9-10 as the 62.6% gross margin scales; 25% tax applied only in profitable years with no NOL benefit modeled; FCF approximated as NOPAT assuming D&A roughly offsets capex; 12% discount rate; 4% terminal growth; net debt of $34.6M ($29.4M cash less $64.0M debt) subtracted from enterprise value; 30.50M shares outstanding.

Reasoning: ClearPoint has high (62.6%) gross margins but is still deeply loss-making (FY2025 net loss of $25.5M, consensus -$39.6M for FY2026), so its equity value depends almost entirely on the speed of its path to profitability, making a long explicit DCF with an aggressive margin-ramp assumption more informative than a static revenue multiple; the resulting ~$2/share value is well below the $10.90 market price and $23.50 average analyst target, implying the market is pricing a faster or larger margin recovery than this conservative model assumes.